AstraZeneca ends two Phase III trials due to enrollment issues
AstraZeneca (NASDAQ:AZN) announced the termination of two significant Phase III trials, STABILIZE-CKD and DIALIZE-Outcomes, from its CRYSTALIZE programme. The decision was made due to...
Buy
or
AstraZeneca News & Analysis
-
-
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
VANCOUVER, Wash., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a leader in generative AI antibody discovery, today announced a collaboration with AstraZeneca, a...
-
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in artificial...
-
Artificial Intelligence used to maintain 6 Million Trees in Kenya
AstraZeneca (LON:AZN) pledges to plant up to six million trees in Kenya and plans to use an AI deep learning model to monitor tree health, long-term survival and carbon sequestration. This...
-
AstraZeneca halts Phase III trials for kidney disease treatment
AstraZeneca (NASDAQ:AZN) plc has announced the discontinuation of its Phase III STABILIZE-CKD and DIALIZE-Outcomes trials, which were investigating treatments for chronic kidney disease...
-
Triple-Negative Breast Cancer Market to Grow Rapidly During the Forecast Period (2023–2032), Predicts DelveInsight | Key Companies in the Market - AstraZeneca, Daiichi Sankyo, Pfizer, OncoSec, Merck, OncoPep, Roche
New York, USA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Triple-Negative Breast Cancer Market to Grow Rapidly During the Forecast Period (2023–2032), Predicts DelveInsight | Key Companies in the...
-
Jefferies maintains AstraZeneca at 'buy' with a price target of £125.0
An analyst from Jefferies maintained AstraZeneca (LON: AZN) at 'buy' with a price target of £125.0 from a prior price target of £130.0. Prior to this rating, AstraZeneca had 24...
-
Barclays updates FTSE stock targets, AstraZeneca and Admiral rise
LONDON - Barclays (LON:BARC) has made a series of recalibrations to its price targets on a range of FTSE-listed stocks, reflecting a mix of optimism and caution in its latest assessments....
-
Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)
AstraZeneca's Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with hormone receptor (HR)-positive,...
-
UK stocks rally on rate cut hopes and AstraZeneca's drug approval
LONDON - UK stocks rebounded on Friday, with the FTSE 100 and FTSE 250 indices climbing by 1.1% and 1.3% respectively, as investor sentiment improved on the back of economic data suggesting...
-
AstraZeneca's Imfinzi misses primary endpoint in Phase III lung cancer trial
CAMBRIDGE, UK - AstraZeneca (NASDAQ:AZN) has announced that its recent PACIFIC-2 Phase III trial, which tested the efficacy of Imfinzi in combination with platinum-based chemoradiotherapy...
-
AstraZeneca's Imfinzi shows promise in liver cancer treatment
AstraZeneca (NASDAQ:AZN)'s immunotherapy drug, Imfinzi (durvalumab), has shown significant improvements in progression-free survival (PFS) for liver cancer patients eligible for...
-
AstraZeneca raises annual profit forecast as China's CPI contracts
In recent financial news, AstraZeneca (NASDAQ:AZN) has raised its annual core profit forecast amidst high demand for oncology and rare blood disorder drugs. The company reported a 4%...
-
AstraZeneca lifts full-year guidance for EPS, revenue despite profit miss
AstraZeneca lifts full-year guidance for EPS, revenue despite profit miss
-
AstraZeneca reports, Li Auto earnings, Tapestry: 3 things to watch
Investing.com -- Stocks wobbled for much of the day on Wednesday, struggling to keep a multi-day rally going as investors continued to absorb earnings reports. Investors also have an...
-
S&P 500 companies gear up for third-quarter reports amid economic indicators
Investors are set to navigate a busy week as numerous S&P 500 companies, including BioNTech (NASDAQ:BNTX), Constellation Energy, Celanese (NYSE:CE), Vertex Pharmaceuticals (NASDAQ:VRTX),...
-
: Cellectis’ stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca
The U.S.-listed shares of Cellectis S.A. CLLS rocketed 179.3% on very heavy volume in premarket trading Wednesday, after the France-based biotechnology company announced an equity investment...
-
Michael Brush: These 3 healthcare stocks should come to life as boomers live their golden years
The baby-boom generation changes every aspect of life it steamrolls through. Now it’s doing the same to healthcare.
-
: AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccine
AstraZeneca PLC AZNUK:AZN said Tuesday the U.S. Food and Drug Administration has accepted its application for approval of a self-administered flu vaccine. The company said the regulator has...
-
FTSE 100 Dips as Fresnillo Leads Losses, Flutter Entertainment Tops Gainers
The FTSE 100 Index UKX closed lower on Monday, slipping by 0.37% to settle at 7,374.83 points. The decline was led by precious metals company Fresnillo PLC (LSE:LON:FRES), which saw a...
-
LumiraDx surges after partnering with AstraZeneca, Everton on England's first heart and lung screening hub
Small-cap LumiraDx Ltd (NASDAQ:LMDX) surged 280% in early trading Monday after announcing a deal late Friday with major pharmaceutical player AstraZeneca (NASDAQ:AZN) and Everton Football...
-
LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England's First Heart & Lung Screening Hub
Made possible thanks to unrestricted grant funding from AstraZeneca and run by the official charity of Everton Football Club – Everton in the Community – the Liverpool-based hub will provide...
-
Why Is AstraZeneca Stock Trading Lower Today?
AstraZeneca Plc (NASDAQ: AZN) shares are trading lower after a data abstract on its experimental drug, datopotamab deruxtecan, for lung cancer patients in a late-stage trial disappointed...
-
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute...
-
AstraZeneca's Tagrisso-Chemo Combo Under FDA Priority Review For Most Common Form Of Lung Cancer
AstraZeneca Plc's (NASDAQ: AZN) supplemental New Drug Application for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the U.S. for...
-
In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK's Benlysta and AstraZeneca's Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global In
Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options...
-
AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug
AstraZeneca Plc (NASDAQ: AZN) has agreed to pay $425 million to settle U.S. lawsuits related to heartburn and stomach acid treatments Nexium and Prilosec. The heartburn treatments have...
-
BofA Securities maintains AstraZeneca at 'buy' with a price target of GBP145.0
An analyst from BofA Securities maintained AstraZeneca (LON: AZN) at 'buy' with a price target of GBP145.0. Prior to this rating, AstraZeneca had 23 buy ratings, 1 hold ratings, and 0 sell...
-
AstraZeneca growth opportunities 'overlooked' - Jefferies
Jefferies upgraded shares of AstraZeneca (LON:AZN) to Buy from Hold, lifting the price target to 13,000p per share, up from 10,500p in a note Monday. Analysts told investors in a note that...
-
Amazon, Warner Bros, and Dow rise premarket; Nio, Nike, HP fall
Investing.com -- U.S. futures edged lower Monday, with investors still reeling from last week’s hawkish Federal Reserve meeting, while a U.S. government shutdown draws nearer. Here are...
-
Deutsche Bank maintains AstraZeneca at 'hold' with a price target of GBP110.0
An analyst from Deutsche Bank maintained AstraZeneca (LON: AZN) at 'hold' with a price target of GBP110.0. Prior to this rating, AstraZeneca had 23 buy ratings, 6 hold ratings, and 0 sell...
-
Berenberg maintains AstraZeneca at 'buy' with a price target of GBP133.0
An analyst from Berenberg maintained AstraZeneca (LON: AZN) at 'buy' with a price target of GBP133.0. Prior to this rating, AstraZeneca had 23 buy ratings, 6 hold ratings, and 0 sell...
-
Jefferies upgrades AstraZeneca to 'buy' with a price target of GBP130.0
An analyst from Jefferies upgraded AstraZeneca (LON: AZN) from 'hold' to 'buy' with a price target of GBP130.0 from a prior price target of GBP105.0. Prior to this rating, AstraZeneca had...
-
Morgan Stanley maintains AstraZeneca at 'overweight' with a price target of GBP127.0
An analyst from Morgan Stanley maintained AstraZeneca (LON: AZN) at 'overweight' with a price target of GBP127.0. Prior to this rating, AstraZeneca had 22 buy ratings, 2 hold ratings, and...
-
JPMorgan advocates for energy stocks, anticipates supply-demand gap post-2025
JPMorgan has recently upgraded its rating on global energy stocks from Neutral to Overweight, predicting a supply-demand gap after 2025 and improving sector fundamentals. The bank...
-
AstraZeneca and Futurize Unveil FuturizeU: Africa’s Healthcare Innovation Hub
Futurize and AstraZeneca (LON:AZN) have officially launched the pioneering HealthTech incubator program, FuturizeU, co-funded by Bristol Myers Squibb, running from September 12 to November...
-
Morgan Stanley maintains AstraZeneca at 'overweight' with a price target of GBP127.00
An analyst from Morgan Stanley maintained AstraZeneca (LON: AZN) at 'overweight' with a price target of GBP127.00 from a prior price target of GBP126.00. Prior to this rating, AstraZeneca...
-
European stocks mixed; strong AstraZeneca numbers help U.K. outperform
Investing.com - European stock markets traded in a mixed fashion Friday, as investors digested a week of corporate earnings, important central bank decisions and economic data. At 03:55 ET...
-
Dow futures steady after snapping rally, Intel lifts 8.4% after earnings
Investing.com - U.S. stock futures were trading marginally higher during Thursday's evening trade, following a negative session among major benchmark averages, with market participants...
-
HSBC initiates coverage of AstraZeneca at 'buy' with a price target of GBP132.50
An analyst from HSBC initiated coverage of AstraZeneca (LON: AZN) at 'buy' with a price target of GBP132.50. Prior to this rating, AstraZeneca had 22 buy ratings, 2 hold ratings, and 0...
-
Midday movers: PepsiCo, Walt Disney, Delta Air Lines and more
Investing.com -- U.S. stocks were rising on Thursday after another inflation report, this time about producer prices, showed prices continuing to cool. Investors are taking in the...
-
PepsiCo, Walt Disney, Delta rise premarket; Carvana, Coinbase SoFi fall
Investing.com -- U.S. futures traded higher Thursday, continuing the recent positive sentiment ahead of the latest data on producer prices, with investors looking for more clues guiding...
-
Morgan Stanley maintains AstraZeneca at 'overweight' with a price target of GBP126.00
An analyst from Morgan Stanley maintained AstraZeneca (LON: AZN) at 'overweight' with a price target of GBP126.00 from a prior price target of GBP132.00. Prior to this rating, AstraZeneca...
-
UBS upgrades AstraZeneca to 'buy' with a price target of GBP130.00
An analyst from UBS upgraded AstraZeneca (LON: AZN) from 'neutral' to 'buy' with a price target of GBP130.00 from a prior price target of GBP125.00. Prior to this rating, AstraZeneca had 22...
-
U.S. stocks are falling as investors await Fed's June minutes
Investing.com -- U.S. stocks were falling as investors awaited the minutes of the latest Federal Reserve policy meeting. At 9:39 ET (13:39 GMT), the Dow Jones Industrial Average was down 140...
-
Jefferies maintains AstraZeneca at 'hold' with a price target of GBP105.00
An analyst from Jefferies maintained AstraZeneca (LON: AZN) at 'hold' with a price target of GBP105.00 from a prior price target of GBP108.00. Prior to this rating, AstraZeneca had 22 buy...
-
Berenberg maintains AstraZeneca at 'buy' with a price target of GBP133.00
An analyst from Berenberg maintained AstraZeneca (LON: AZN) at 'buy' with a price target of GBP133.00 from a prior price target of GBP135.00. Prior to this rating, AstraZeneca had 22 buy...
-
Deutsche Bank downgrades AstraZeneca to 'hold' with a price target of GBP110.00
An analyst from Deutsche Bank downgraded AstraZeneca (LON: AZN) from 'buy' to 'hold' with a price target of GBP110.00 from a prior price target of GBP130.00. Prior to this rating,...
-
Asian stocks struggle amid economic jitters, Nikkei slides
Investing.com -- Most Asian stocks moved in a flat-to-low range on Tuesday as a string of weak data prints from major economies dented risk appetite, with Japanese stocks falling the most as...
-
Midday movers: Tesla, AstraZeneca, Carnival Corp. and more
Investing.com -- Stocks are rising in light trading on a shortened market day in the U.S. session. Here are the market movers for July 3. Tesla Inc (NASDAQ:TSLA) shares rose 6% after the...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
